Genetic Mutation Test Kit

This kit is employed for the in vitro qualitative detection of 14 types of ROS1 fusion gene mutations in human non-small cell lung cancer samples (Table 1). The test results are intended for clinical reference only and should not be the sole basis for the individualized treatment of patients. Clinicians should formulate comprehensive assessments of the test results by considering the patient’s condition, drug indications, treatment response, and other laboratory test indicators.

ROS1 is a member of the insulin receptor family and is a transmembrane tyrosine kinase. Another significant non-small cell lung cancer driver gene has been identified as the ROS1 fusion gene. The incidence of the ROS1 fusion gene in NSCLC is approximately 1% to 2%, indicating that it is a representative of a new, distinctive molecular subtype [1,2]. The exons 32, 34, 35, and 36 of ROS1 are the primary sites of gene rearrangement. Following its fusion with genes such as CD74, EZR, SLC34A2, and SDC4, it will continue to activate the ROS1 tyrosine kinase region. Abnormally activated ROS1 kinase can activate downstream signaling pathways, including RAS/MAPK/ERK, PI3K/Akt/mTOR, and JAK3/STAT3, thereby contributing to the proliferation, differentiation, and metastasis of tumor cells and causing cancer [2].